Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition), 2021-2030: Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, and specific BET and DUB inhibitors and other inhibitors), Therape

Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition), 2021-2030: Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, and specific BET and DUB inhibitors and other inhibitors), Therapeutic Area (Neurological Disorders, Oncological Disorders, and Other Therapeutic Areas), Route of administration (Oral, Intravenous and Others), Key Contributing Technologies and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)

Targeted protein degradation is a revolutionary pharmacological concept that presents viable drug development opportunities and is anticipated to introduce a new paradigm in modern therapeutic interventions. Due to various reasons, conventional drugs / therapies have been limited in terms of their capability to target certain proteins of pathological significance. Presently, medical researchers engaged in the development of bifunctional protein degrader-based interventions claim that this upcoming class of drugs is capable of targeting biomolecules in the human proteome, which were previously considered undruggable. The concept of targeted protein degradation revolves around the use of small molecule leads, which are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target biomolecule. In other words, protein degraders regulate biological pathways by selectively downregulating a target protein by degrading them; this process has been shown to be robust, more sensitive to drug-resistant targets and can regulate cellular functions that are not dependent on enzyme action. Moreover, drugs designed based on this relatively novel concept, have been shown to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, compared to traditional enzyme inhibitors. As a result, this upcoming class of drugs has garnered significant interest within the medical science community. In fact, the growing popularity of targeted protein degradation is evident in the USD 5 billion in capital investments made into companies engaged in this field of research, since 2014.

Proteolysis targeting chimera (PROTAC), developed by Hashimoto Laboratory in 2008, was the first targeted protein degrader. The incessant efforts of researchers involved in this domain have resulted in significant progress towards understanding the physiochemical and biological properties of such bifunctional molecules. Presently, there are several other types of targeted protein degraders and molecular glues, which have been / are being developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. It is worth noting that the R&D efforts in this field are supported by DNA-encoded libraries and other in silico hit discovery and characterization tools. In the last 4-5 years, there has been a marked rise in the number of new entrants in this market. Additionally, several big pharma players are also actively involved in this field, evaluating proprietary protein degrader-based therapeutic leads. The market has also witnessed substantial partnership activity over the last few years, with several technology developers involved in high-value licensing deals. Although, there are no approved protein degrader-based drugs / therapy products, the market is poised to witness healthy growth over the next decade.

The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition), 2021-2030: Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, and specific BET and DUB inhibitors, and other inhibitors), Therapeutic Area (Neurological Disorders, Oncological Disorders, and Other Therapeutic Areas), Route of administration (Oral, Intravenous and Others), Key Contributing Technologies and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)’ report features an extensive study of the current and future potential of protein degraders, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. In addition, the report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
 A detailed review of the current market landscape of targeted protein degradation-based therapeutics, including information on type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of biological target(s), associated ubiquitin ligase(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others). In addition, it presents a list on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s).
 An overview of the overall landscape of target protein degradation enabling technologies, featuring an analysis based on type of degrader. In addition, it presents a list of targeted protein degradation enabling technology developers and analysis based on various parameters, such as year of establishment, company size and location of headquarters.
 Detailed profiles of prominent players engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each profile features a brief overview of the company, its financial information (if available), detailed description of their respective lead drug candidates, and recent developments and an informed future outlook. Additionally, each drug profile features information on the type of drug, current status of development, route of administration, target indications, and a brief summary of its developmental history.
 Tabulated profiles of leading industry players (shortlisted on the basis of the number of candidates in development pipeline). Each profile includes details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with information on respective drug candidates.
 An in-depth analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), trial focus, target therapeutic area, key indications, and clinical endpoints.
 A detailed analysis of grants that have been awarded to various research institutes for targeted protein degradation projects, in the period between 2017 and 2020, on the basis of important parameters, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, study section, popular NIH departments, study section, and type of recipient organization, highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.
 A detailed publication analysis peer-reviewed, scientific articles that have been published between 2017 and Q3 2019, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of protein degrader, biological target, associated ubiquitin enzyme, number of publications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal).
 An insightful analysis of the patents filed / granted for targeted protein degradation enabling technologies, since 2018, taking into consideration various parameters, such as type of patent, publication year, geographical location, type of applicant, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. The chapter also includes a detailed patent benchmarking and an insightful valuation analysis.
 A list of key opinion leaders (KOLs) within this domain, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
 An analysis of the partnerships that have been established in this domain, during the period 2014-2020, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
 An analysis of the investments in the form of seed financing, venture capital financing, debt financing, grants / awards, initial public offerings (IPOs) and subsequent offerings, made at various stages of development of the companies engaged in this field.
 A detailed deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities of novel technologies for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided informed estimates on the evolution of the market over the period 2021-2030. For estimating the future market opportunities for technology providers, we have considered the likely licensing deal structures and agreements that are likely to be established in the foreseen future. The future opportunity within the targeted protein degradation market has been segmented across [A] different types of protein degraders (degronimids, PROTACs, SARDs / SERDs, Specific BET and DUB Inhibitors, and other inhibitors), [B] therapeutic areas (oncological disorders, neurological disorders, and other therapeutic areas), [C] route of administration (oral route, intravenous route, and other routes), and [D] key geographical regions (North America, Europe and Asia Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):
 Laura Itzhaki, Founder and Chief Scientific Officer, Polyprox Therapeutics
 Louise Bergeron, Vice President, Xios Therapeutics
 Martin Wiles, Vice President Business Development and Licensing, Almac Discovery & Gerald Gavory, Director of Biology, Almac Discovery
 Jason Brown, Scientific and Business Development Director, Ubiquigent
 Anonymous, Director of Oncology Research, Large Company
 Anonymous, Chief Scientific Officer, Very Small Company
 Paul Wallace, Chief Business Officer, Mission Therapeutics
 Katrin Rittinger, Research Group Leader, Francis Crick Institute
 Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry, University of Delaware
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

1.1. RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources.

The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views
While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

1.2. KEY QUESTIONS ANSWERED
 Who are the leading industry and non-industry players engaged in this market?
 What are the key therapeutic areas for which target protein degraders are being / have been developed?
 Which geographies are the most active in conducting clinical trials on target protein degraders?
 What kind of partnership models are commonly adopted by industry stakeholders?
 Which are the leading administering institute centers supporting the research related to this domain?
 What is the trend of capital investments in the targeted protein degradation market?
 How has the intellectual property landscape in this market evolved over the years?
 How is the current and future market opportunity likely to be distributed across key market segments?

1.3. CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of targeted protein degradation-based drugs market and its likely evolution in the short-mid- term and long term.

Chapter 3 provides an introduction to protein homeostasis, including a discussion on the UPS for intracellular protein degradation and turnover. It presents an elaborate discussion on the structure and function of ubiquitin, various components of the UPS and key steps involved in the UPS-based protein degradation. Further, the chapter provides an overview of the concept of targeted protein degradation, including details on various protein degraders and their associated pathways and mechanisms of action. The chapter also includes a discussion on the historical evolution, importance, advantages and challenges associated with the use of targeted protein degradation as a therapeutic principle. In addition, the chapter describes the key growth drivers and roadblocks related to targeted protein degraders, offering insights on the upcoming trends in the domain.

Chapter 4 includes information on more than 155 targeted protein degraders that are currently being evaluated in different stages of development (both clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules, based on their types of protein degraders (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indications, key therapeutic areas, types of target proteins, target enzymes (if available), target signaling pathways (if available), mechanisms of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, location of headquarters and company size.

Chapter 5 provides an overview of the overall landscape of the targeted protein degradation enabling technologies, including an analysis based on type of degrader. In addition, the chapter features a list of technology developers and an analysis based on several parameters, such as such as year of establishment, company size, and location of headquarters.

Chapter 6 features elaborate profiles of prominent players engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each company profile includes a brief overview of the company, its financial information (if available), details on their respective lead drug candidates, recent development and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history. Further, the chapter includes tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the developer (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.

Chapter 7 provides a detailed analysis of completed, ongoing and planned clinical studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.

Chapter 8 provides an analysis of more than 770 grants that were awarded to research institutes engaged in target protein degradation, in the period between 2017 and 2020 based on the important parameters, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, study section, popular NIH departments, study section, type of recipient organizations, popular recipient organizations, popular program officers and regional distribution.

Chapter 9 provides information on certain recent publications that we came across during our research on target protein degradation. This chapter highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of protein degrader, biological target, associated ubiquitin enzyme, number of publications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal).

Chapter 10 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to target protein degradation, since 2018, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.

Chapter 11 provides an analysis of KOLs in the field of targeted protein degradation. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation of a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criterion, which was based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

Chapter 12 features an elaborate discussion and analysis of collaborations and partnerships that have been inked between different players in this market since 2014. It includes a brief description of various types of partnership models (such as research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to targeted protein degraders. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 13 provides information on funding instances and investments that have been made within the targeted protein degradation domain. The chapter includes details on the capital (in the form of seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies in the period 2014-2020, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of novel technologies designed for the development of targeted protein degraders till the year 2030, based on licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] different types of protein degraders (degronimids, PROTACs, SARDs / SERDs, Specific BET and DUB Inhibitors, and other inhibitors), [B] therapeutic areas (oncological disorders, neurological disorders, and other therapeutic areas), [C] route of administration (oral route, intravenous route, and other routes), and [D] key geographical regions (North America, Europe and Asia Pacific).

Chapter 15 provides deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

Chapter 16 is a collection of interview transcripts of discussions held with key stakeholders in this market.

Chapter 17 is a summary of the overall report. It presents the key takeaways and offers our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which contains the list of companies and organizations.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies / organizations have been mentioned in this report.
1. 6 Dimensions Capital
2. AbbVie
3. Abingworth
4. Advantech Capital
5. Advent Life Sciences
6. AIHC Capital
7. Aisling Capital
8. AJU IB Investment
9. Alexandria Venture Investments
10. Alfred Berg
11. Almac Discovery
12. Alpha Stem Cell Clinic
13. Altitude Life Science Ventures
14. AM Capital
15. Amgen
16. Amgen Ventures
17. Amphista Therapeutics
18. Amzak Health
19. ARCH Venture Partners
20. Arpeggio Biosciences
21. Arvinas
22. AstraZeneca
23. Atlas Venture
24. Avista Pharma Solutions
25. Bain Capital Life Sciences
26. Bayer
27. Beactica
28. BeiGene
29. Bellco Capital
30. Bessemer Venture Partners
31. Beth Israel Deaconess Medical Center
32. BeyondSpring Pharmaceuticals
33. Biogen
34. BioMotiv
35. BioRap Technologies
36. Biotech Investment Fund
37. BioTheryX
38. BlackRock
39. Boehringer Ingelheim
40. Borun Investment
41. Brigham And Women's Hospital
42. Bristol Myers Squibb
43. BVF Partners
44. C4 Therapeutics
45. Calico
46. California Institute for Regenerative Medicine
47. Cambridge Enterprise
48. Cambridge Innovation Capital
49. Cambridge Stem Cell Institute
50. Cancer Prevention & Research Institute of Texas
51. Cancer Research Technology
52. Cancer Research UK Manchester Institute
53. Capital Pathology Bega
54. Captor Therapeutics
55. Cardinal Partners
56. Carmot Therapeutics
57. Casdin Capital
58. CCB Medical Devices
59. Cedilla Therapeutics
60. Celgene
61. CellCentric
62. Centre for Clinical Hematology, Queen Elizabeth Hospital
63. Chengdu Dingjian
64. Children's Hospital of Philadelphia, University of Pennsylvania
65. China Construction Bank
66. Chugai Pharmaceuticals
67. ClinAssess
68. CMB International Capital
69. Cobro Ventures
70. Cormorant Asset Management
71. Cosmo Bio
72. Covance
73. Cowen
74. Cowen Private Investments
75. Crede Capital Group
76. Cullgen
77. CVC Capital Partners
78. Cyclofluidic
79. Dana-Farber Cancer Institute
80. DCVC
81. Deerfield Management
82. Dialectic Therapeutics
83. DMS Group
84. Dorian Therapeutics
85. DROIA Ventures
86. Duke University
87. Dyee Capital
88. E Fund Management
89. EcoR1 Capital
90. EG Capital
91. Eisai
92. Elan Science One
93. Eli Lilly
94. Emeriti Bio
95. EMN Research Italy
96. Eriksam Invest Aktiebolag
97. Eshelman Ventures
98. Eternal Thrive
99. European Investment Fund
100. European Myeloma Network
101. European Regional Development Fund
102. Eventide Asset Management
103. Evotec
104. Farallon Capital Management
105. Fidelity Biosciences
106. FIMECS
107. Five Elements Bio-technology
108. Fjärde AP-fonden
109. Foresite Capital
110. FORMA Therapeutics
111. Fosun
112. Franklin Templeton Investments
113. Fred Hutchinson Cancer Research Center
114. Frontier Medicines
115. G1 Therapeutics
116. Genentech
117. GF Xinde Investment Management
118. Gilead Sciences
119. GL Ventures
120. Gladiator
121. GlaxoSmithKline
122. GMIHO Medizinische Innovation -Hämatologie und Onkologie
123. GNI Group
124. GV
125. GVK Biosciences
126. H. Lee Moffitt Cancer Center and Research Institute
127. Haisco Pharmaceutical
128. Handelsbanken Fonder
129. Harvard Medical School
130. Hatteras Venture Partners
131. HBM Healthcare Investments
132. Healt Data Specialists
133. HealthCap
134. HealthCare Ventures
135. Hermed Alpha
136. HighLight Capital
137. Hinova Pharmaceuticals
138. HitGen
139. Honghui Capital
140. Horizon Discovery
141. Horizons Venture
142. Huarong Rongde Asset Management
143. Hybrigenics Pharma
144. IGM Biosciences
145. ImmunoLogik
146. Imperial Innovations
147. INIM Pharma
148. Innovate UK
149. Institute of Cancer And Genomic Science
150. Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
151. InventisBio
152. Invus
153. IP Group
154. Janchor Partners
155. Janpix
156. Janssen Research & Development
157. Janus Henderson Investors
158. Jiangsu HengRui Medicine
159. Kai Kuang Pharmaceutical
160. Kangpu Biopharmaceuticals
161. Kronos Bio
162. Kymera Therapeutics
163. Kyoto University Innovation Capital
164. Lang Sheng Investment Group
165. Legend Biotech
166. Lenovo Star
167. LifeArc
168. Lilly Asia Ventures
169. Lilly Ventures
170. Longwood Fund
171. Loxo Oncology
172. Lumira Capital
173. Lycia Therapeutics
174. M Ventures
175. M.D. Anderson Cancer Center
176. Macroceutics
177. Massachusetts General Hospital
178. Matrix Capital
179. Matrix Partner China
180. McGill University
181. MD Anderson Cancer Center
182. MedImmune Ventures
183. Medivir
184. Memorial Sloan Kettering Cancer Center
185. Menarini Group
186. Merck
187. Mirae Asset Capital
188. Mission Therapeutics
189. Monte Rosa Therapeutics
190. Moonstone Investments
191. Morningside Venture Investments
192. Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute
193. Mountain Group Partners
194. MPM Capital
195. MRL Ventures Fund
196. Mubadala Ventures
197. Nanjing General Hospital of People's Liberation Army
198. Nanologica
199. National Cancer Institute
200. National Centre for Research and Development
201. National Institute of Genetics
202. National Institute of Health
203. Neotribe Ventures
204. New Enterprise Associates
205. Nextech Invest
206. Nordic Cross
207. Novartis
208. Novartis Institutes for BioMedical Research
209. Novartis Venture Fund
210. Nuevolution
211. Nurix Therapeutics
212. Nyenburgh Investment Partners
213. Oerth Bio
214. Ohio State University
215. Omega Funds
216. Oncternal Therapeutics
217. OrbiMed
218. Oriental Securities Capital
219. Orionis Biosciences
220. Oxford Finance
221. Parexel
222. Penn Medicine Abramson Cancer Center
223. Perceptive Advisors
224. Pfizer
225. Pfizer Ventures
226. Pin Therapeutics
227. Plexium
228. Polaris Partners
229. PolyProx Therapeutics
230. Profacgen
231. Progenra
232. Promega
233. Prostate Cancer Foundation
234. Proteostasis Therapeutics
235. Providence Investment
236. Proxygen
237. Pudong Innotek
238. Qiming Venture Partners
239. Queen's University
240. Quotient Sciences
241. RA Capital
242. Radius Health
243. Redmile Group
244. Roche
245. Roche Venture Fund
246. Rock Springs Capital
247. Rockefeller University
248. Roivant Sciences
249. Roswell Park Cancer Institute
250. RT Capital
251. Samus Therapeutics
252. Sanofi Genzyme
253. Sanofi Ventures
254. Schroder Adveq
255. Scottish Investment Bank
256. Seed Therapeutics
257. Sequoia Capital China
258. Seragon Pharmaceuticals
259. Servier
260. Shanghai Free Trade Zoon Equity Fund
261. Shanghai Furong Investment
262. Shenzhen Guozhong Venture Capital
263. Shenzhen Investment Holdings
264. Shenzhen Sangel Zhichuang Investment
265. SinoPharm Capital
266. Sitryx Therapeutics
267. SK Holdings
268. Sofinnova Partners
269. Solar Capital
270. Songhe Capital
271. Sosei Heptares
272. SR One
273. St. Antonius Hospital
274. Stanford University
275. Sun Pharma Advanced Research Company
276. Surveyor Capital
277. Suzhou Pioneer Pharmaceutical
278. SV Health Investors
279. SV Torch
280. Swedbank Robur
281. Sygnature Discovery
282. Takeda Pharmaceutical
283. Tavistock Life Sciences
284. Tavros Therapeutics
285. Tetralogic Pharmaceuticals
286. The Chinese University of Hong Kong
287. The Column Group
288. The Institute of Cancer Research
289. The Kraft Group
290. The Michael J. Fox Foundation
291. The Netherlands Cancer Institute
292. The Silverstein Foundation for Parkinson’s with GBA
293. Third Rock Ventures
294. Tigermed
295. Tokalas
296. Trilo Therapeutics
297. Trinitas Capital
298. Tybourne Capital Management
299. UbiQ Bio
300. Ubiquigent
301. Ubix Therapeutics
302. UCLA Jonsson Comprehensive Cancer Center
303. Unionen
304. University Health Network
305. University Hospital Erlangen
306. University Hospital of Würzburg
307. University of California, Berkeley
308. University of California, San Francisco
309. University of Dundee
310. University of Florida
311. University of Illinois
312. University of Liverpool
313. University of Maryland, Baltimore
314. University of Michigan
315. University of Oxford
316. University of Southern Denmark
317. University of Tennessee Research Foundation
318. University of Washington
319. Vagelos College of Physicians and Surgeons
320. Versant Ventures
321. Vertex Pharmaceuticals
322. Vicore Pharma
323. Vida Ventures
324. Viking Global Investors
325. Vividion Therapeutics
326. VU University Medical Center
327. Washington University School of Medicine
328. Weill Medical College of Cornell University
329. Wellington Management
330. Woodford Patient Capital Trust
331. Wrocław Research Centre EIT+
332. X-Chem
333. Xios Therapeutics
334. Yale University
335. Yissum
336. Yuanhe Holdings
337. Yuansheng Venture Capital
338. Zenopharm
339. Zentalis Pharmaceuticals
340. Zentera
341. Zhuhai Huajin Capital

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.